Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lowell Ku

Reproductive Endocrinology Frisco, TX Medical Doctor

NPI 1184642274 CMS profile 98369

2840 Legacy Dr, Suite 100, Frisco, TX 75034

Open in the dashboard

General payments

$12,235

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lowell Ku of Frisco, TX is reported in the CMS Open Payments database as having received $12,235 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,447 29
2024 General $1,360 29
2023 General $1,170 18
2022 General $283 22
2021 General $277 24
2020 General $1,844 13
2019 General $5,854 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lowell Ku
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Lowell Ku were reported at $1,447. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Lowell Ku Reproductive Endocrinology median Middle half National median
2019 $5,854 $196 $77–$425 $163
2020 $1,844 $81 $35–$182 $114
2021 $277 $102 $43–$247 $132
2022 $283 $139 $62–$303 $149
2023 $1,170 $141 $65–$285 $160
2024 $1,360 $144 $65–$302 $164
2025 $1,447 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ferring Pharmaceuticals Inc. $6,137 105 payments
  2. Merck Sharp & Dohme Corporation $3,980 12 payments
  3. Hamilton Thorne, Inc. $500 1 payment
  4. Organon LLC $480 27 payments
  5. CooperSurgical, Inc. $401 6 payments
  6. EMD Serono, Inc. $346 5 payments
  7. AbbVie, Inc. $180 5 payments
  8. Covidien LP $151 1 payment
  9. Hologic, LLC $36 2 payments
  10. Mission Pharmacal Company $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,379 3 payments
  2. Food and Beverage $3,101 153 payments
  3. Travel and Lodging $2,125 7 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,630 2 payments
Products named General payments · program years 2019–2025
  1. MENOPUR Reproductive Health $2,192 61 payments
  2. INVOCELL $1,449 3 payments
  3. MENOPUR Reproductive Health $521 35 payments
  4. SOFT-PASS $500 1 payment
  5. GANIRELIX ACETATE $345 16 payments
  6. PREGNYL $338 18 payments
  7. FOLLISTIM AQ $307 14 payments
  8. STRIPPER $206 3 payments
  9. Orilissa $158 4 payments
  10. TruClear $151 1 payment
  11. Other $509 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record